Skip to main content
. 2012 Apr 26;1(1):2–11. doi: 10.1016/j.jbo.2012.03.001

Fig. 4.

Fig. 4

Therapeutic arsenals currently used or in development targeting osteoclast lineage to treat bone tumours. These therapeutic approaches target osteoclasts, their differentiation and/or their activation by blocking RANKL binding to RANK, by signal transduction, cell adhesion and migration or enzymatic activities.